A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Clinical trial NCT03051217 · COMPLETED

Trial details

NCT number: NCT03051217
Sponsor: UCB Biopharma S.P.R.L.
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Moderate to Severe Psoriasis Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Start date: 2017-02-21
Primary completion: 2018-11-19
Enrollment: 127

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.